Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Abildgaard

Showing results (191-200 of 203) with videos related to

Pageof 21
Sort By:
Nouvelle Revue Francaise D'Hematologie|January 1, 1994
Plasma thrombomodulin level in malignancy varies according to the tumor typeM C Boffa, C Lapeyrère, M Berard, et al.
Acta Physiologica Scandinavica|February 1, 1988
Effect of renal venous pressure elevation on tubular sodium and water reabsorption in the dog kidneyU Abildgaard, O Amtorp, N H Holstein-Rathlou, et al.
Journal of Thrombosis and Haemostasis : JTH|December 23, 2004
Tissue factor pathway inhibitor revisitedP F Hjort, P M Sandset, U Abildgaard, et al.
The Journal of Biological Chemistry|September 27, 1996
Structure and anticoagulant activity of a fucosylated chondroitin sulfate from echinoderm. Sulfated fucose branches on the polysaccharide account for its high anticoagulant actionP A Mourão, M S Pereira, M S Pavão, et al.
Thrombosis Research|December 1, 1991
A common point mutation producing type 1A antithrombin III deficiency: AT129 CGA to TGA (Arg to Stop)R J Olds, D A Lane, H Ireland, et al.
European Heart Journal|December 1, 1985
Bed rest and increased diuretic treatment in chronic congestive heart failureU Abildgaard, J Aldershvile, H Ring-Larsen, et al.
Thrombosis Research|June 15, 1991
Extrinsic pathway inhibitor (EPI) released to the blood by heparin is a more powerful coagulation inhibitor than is recombinant EPIA K Lindahl, U Abildgaard, M L Larsen, et al.
Haemostasis|January 1, 1986
Subcutaneous heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparinH A Holm, B Ly, G F Handeland, et al.
The Journal of Clinical Investigation|December 1, 1992
Pleiotropic effects of antithrombin strand 1C substitution mutationsD A Lane, R J Olds, J Conard, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|February 1, 1994
Microheterogeneity of antithrombin III: effect of single amino acid substitutions and relationship with functional abnormalitiesV De Stefano, G Leone, S Mastrangelo, et al.
Pageof 21

Showing results (191-200 of 203) with videos related to

Sort By:
Pageof 21
Nouvelle Revue Francaise D'Hematologie|January 1, 1994
Plasma thrombomodulin level in malignancy varies according to the tumor typeM C Boffa, C Lapeyrère, M Berard, et al.
Acta Physiologica Scandinavica|February 1, 1988
Effect of renal venous pressure elevation on tubular sodium and water reabsorption in the dog kidneyU Abildgaard, O Amtorp, N H Holstein-Rathlou, et al.
Journal of Thrombosis and Haemostasis : JTH|December 23, 2004
Tissue factor pathway inhibitor revisitedP F Hjort, P M Sandset, U Abildgaard, et al.
The Journal of Biological Chemistry|September 27, 1996
Structure and anticoagulant activity of a fucosylated chondroitin sulfate from echinoderm. Sulfated fucose branches on the polysaccharide account for its high anticoagulant actionP A Mourão, M S Pereira, M S Pavão, et al.
Thrombosis Research|December 1, 1991
A common point mutation producing type 1A antithrombin III deficiency: AT129 CGA to TGA (Arg to Stop)R J Olds, D A Lane, H Ireland, et al.
European Heart Journal|December 1, 1985
Bed rest and increased diuretic treatment in chronic congestive heart failureU Abildgaard, J Aldershvile, H Ring-Larsen, et al.
Thrombosis Research|June 15, 1991
Extrinsic pathway inhibitor (EPI) released to the blood by heparin is a more powerful coagulation inhibitor than is recombinant EPIA K Lindahl, U Abildgaard, M L Larsen, et al.
Haemostasis|January 1, 1986
Subcutaneous heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparinH A Holm, B Ly, G F Handeland, et al.
The Journal of Clinical Investigation|December 1, 1992
Pleiotropic effects of antithrombin strand 1C substitution mutationsD A Lane, R J Olds, J Conard, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|February 1, 1994
Microheterogeneity of antithrombin III: effect of single amino acid substitutions and relationship with functional abnormalitiesV De Stefano, G Leone, S Mastrangelo, et al.
Pageof 21